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Abstract: Subcutaneous sumatriptan is an effective treatment for pain from acute migraine 
headache, and can be used in patients with known migraine syndrome and in patients with 
primary headaches when secondary causes have been excluded. In limited comparative trials, 
subcutaneous sumatriptan performed in a manner comparable with oral eletriptan and intravenous 
metoclopramide, was superior to intravenous aspirin and intramuscular trimethobenzamide-
diphenhydramine, and was inferior to intravenous prochlorperazine for pain relief. The most 
common side effects seen with subcutaneous sumatriptan are injection site reactions and triptan 
sensations. As with all triptans, there is a risk of rare cardiovascular events with subcutaneous 
sumatriptan and its use should be limited to those without known cerebrovascular disease and 
limited in those with known cardiovascular risk factors and unknown disease status. In studies 
of patient preference and tolerability, the subcutaneous formulation has a faster time of onset and 
high rate of efficacy when compared with the oral formulation, but the oral formulation appears 
to be better tolerated. It is important to consider the needs of the patient, their past medical his-
tory, and what aspects of migraine treatment are most important to the patient when considering 
treatment of acute migraine or primary headache. Subcutaneous sumatriptan is a good first-line 
agent for the treatment of pain from acute migraine headaches and primary headaches.
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Introduction
Sumatriptan belongs to a class of medications known as the triptans. Sumatriptan, 
the first of these medications, was introduced in the early 1990s and revolutionized 
the current treatment of migraine. Like other triptans, sumatriptan is an agonist at the 
serotonin 5HT1B and 5HT1D receptor subtypes. Sumatriptan has demonstrated efficacy 
when administered by the subcutaneous, oral, intranasal, or rectal route.
Although sumatriptan is primarily used and studied in the setting of migraine 
headache, it is also an effective agent for cluster headaches.1 The recent literature has 
also shown that sumatriptan can be safely and effectively used in patients with pri-
mary headache, ie, headaches that are not secondary to a discrete pathology, including 
migraine, probable migraine, tension, and cluster headaches.2 This review will focus on 
the efficacy, safety, and patient acceptability and compliance concerning subcutaneous 
administration of sumatriptan for the treatment of migraine and primary headache.
The exact mechanism of action of triptans is unclear. Initially they were thought 
to promote vasoconstriction of cerebral vessels that are abnormally vasodilated during 
migraine headaches and possibly inhibit areas of neurogenic inflammation around these 
blood vessels.3 However, sumatriptan likely also acts by reducing neuronal activity 
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within the trigeminovascular system.4–7 Further, sumatriptan 
may block the release of vasoactive neuropeptides from 
both peripheral and central trigeminal neurons by binding to 
5-HT1B/D receptors presynaptically, preventing central sensi-
tization and therefore migraine-associated hyperalgesia.8 It 
has also been shown that triptans modulate transmission of 
trigeminovascular neurons at the level of the thalamus4 and 
periaqueductal gray matter,9 suggesting that triptans may act 
at a higher level of the brain than was previously thought to 
regulate painful sensory information.4
Efficacy
All triptans have been shown to be superior to placebo for 
the treatment of acute migraine headaches. Of the varied 
delivery systems, subcutaneous sumatriptan has been shown 
in multiple studies to have the fastest onset of pain relief.3
Subcutaneous sumatriptan at a dose of 6 mg is quickly 
absorbed, with a time to maximum plasma concentration of 
approximately 10 minutes and an average bioavailability 
of 96%. Other routes of administration for sumatriptan, 
including oral, intranasal, and rectal, have a longer time to 
maximum plasma concentration, much closer to 1.5 hours, 
with bioavailability ranging from 14% to 19%.3
In two landmark studies, subcutaneous sumatriptan was 
shown to work better than placebo for the treatment of acute 
migraine. In 1991, Cady et al randomized otherwise healthy 
adult patients with migraine to subcutaneous sumatriptan 
(n = 734) or placebo (n = 370).10 These authors found that 
sumatriptan was more effective than placebo in reducing 
moderate or severe pain to mild or no pain (70% versus 22%), 
completely relieving headaches (49% versus 9%), improving 
clinical disability (76% versus 34%), and reducing nausea 
and photophobia.
A second study in 1991 randomized 639 patients to 6 mg 
or 8 mg of subcutaneous sumatriptan or placebo.11 Those 
treated with sumatriptan had marked improvement in their 
headache at one hour and 2 hours as compared with those 
who received placebo. There was no significant difference 
noted between the 6 mg and 8 mg doses. Sumatriptan was 
also found to be more effective in reducing nausea, vomiting, 
photophobia, and phonophobia. Further, more participants 
treated with sumatriptan were able to function normally 
at one hour and 2 hours after administration of medica-
tion compared with placebo. In both of these early studies, 
patients who did not obtain relief from their initial dose of 
sumatriptan were given a second dose. The second dose of 
sumatriptan one hour after the first did not show any benefit 
in improving headache pain. These studies established that 
6 mg of subcutaneous sumatriptan is an effective approach 
to treating migraine headache.
In 2000, Tfelt-Hansen et al summarized the results of 13 
double-blind, randomized controlled trials in which subcu-
taneous sumatriptan 6 mg had been compared with placebo. 
This review included 2108 patients treated with sumatriptan, 
70% of whom had headache relief after one hour versus 
19% of 1307 patients treated with placebo. Therefore, the 
therapeutic gain, ie, the percentage responding to active 
drug minus the percentage responding to placebo, was 51% 
(70%–19%). In ten of these trials, the therapeutic gain was 
similar at 2 hours, indicating that the one-hour time frame 
was adequate for reassessment.3
In contrast, the therapeutic gain for 100 mg of oral suma-
triptan was found to be 32% two hours after administration in 
a review of 20 double-blind, placebo-controlled, randomized 
trials including 2928 patients treated with sumatriptan and 
1653 patients treated with placebo.3
The efficacy of subcutaneous sumatriptan was also 
examined in a 2001 review of the use of triptans in Canada. 
The authors included only randomized placebo-controlled 
trials and calculated the therapeutic gain. They found that 
one hour after treatment subcutaneous sumatriptan clearly 
had the highest therapeutic gain (50.98%; 95% confidence 
interval [CI] 47.7–54.21) compared with oral sumatriptan 
100 mg, oral and wafer rizatriptan 10 mg, and oral zolmi-
triptan 2.5 mg. Two hours after administration, subcutaneous 
sumatriptan also had the highest therapeutic gain (49.7%; 
95% CI 43.8–55.7), but now closely followed by wafer riza-
triptan 10 mg (therapeutic gain 46.4%; 95% CI 37.3–55.5). 
A similar trend was observed for patients who were pain-free 
at one and two hours. Subcutaneous sumatriptan also had the 
highest therapeutic gain in clinical disability score of zero at 
one or 2 hours. The authors commented that subcutaneous 
sumatriptan may be the best option for patients who have 
migraine with rapid progression to severe intensity associated 
with high clinical disability.12
In a third systematic review of randomized   controlled 
trials for acute migraine in 2002 by Oldman et al, 
  subcutaneous sumatriptan showed similar results to the 
previous two reviews outlined. Other drugs included in this 
review were intranasal dihydroergotamine + suma  triptan, 
oral aspirin + metoclopramide, ergotamine + caffeine, 
paracetamol + aspirin, naratriptan, rizatriptan, sumatrip-
tan, rapid-release tolfenamic acid, and zolmitriptan. Data 
on eletriptan from clinical trials by Pfizer Inc were also 
included. The authors calculated the number needed to 
treat as the reciprocal of the therapeutic gain, which can be 
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interpreted as the number of people needed to treat in order 
to observe a positive outcome as compared with placebo. 
For headache relief, subcutaneous sumatriptan had the 
greatest efficacy at one hour after administration, with a 
number needed to treat of 2.1 (95% CI 1.9–2.2) as compared 
with the next lowest number needed to treat, ie, intranasal 
dihydroergotamine 2 mg (3.4; 95% CI 2.4–5.9). It also had 
the greatest efficacy at 2 hours and a number needed to treat 
of 2.0 (95% CI 1.8–2.2). Multiple other drugs had numbers 
needed to treat in the upper 2–3 range and were statistically 
equivalent. For pain-free headache relief at 2 hours, subcu-
taneous sumatriptan clearly had the highest efficacy. For 
pain-free headache relief at 24 hours, oral eletriptan 80 mg 
was superior (number needed to treat 2.8; 95% CI 2.5–3.2) 
to subcutaneous sumatriptan (number needed to treat 3.2; 
95% CI 2.4–4.8).13
In 2009, the European Federation of Neurological Soci-
eties reviewed the available literature on clinical studies of 
migraine, migraine with aura, and migraine-like attacks. 
Based on their review of the literature and the expert opinion 
of the authors, they gave graded recommendations for drug 
treatment of pain from acute migraine headaches. Triptans 
were given a level A recommendation based on the previous 
literature. The authors recommended 6 mg of subcutaneous 
sumatriptan or intravenous aspirin with or without metoclo-
pramide as first-line agents in the emergency treatment of 
acute migraine.14
Additionally, practice guidelines from the US Headache 
Consortium recommend triptans as the initial choice for the 
treatment of pain from acute moderate to severe migraine 
headaches in patients who have no contraindications to 
these medications. This recommendation is based on grade 
A evidence, ie, multiple, randomized controlled trials with 
consistent results. The authors recommended that patients 
with nausea or vomiting be given intranasal or subcutane-
ous sumatriptan, and that triptans may be used as the initial 
treatment for pain from migraine headaches of any severity 
when other medication have previously failed to provide 
pain relief. Both of these are grade C (expert consensus) 
recommendations.15
Subcutaneous sumatriptan has been widely studied and 
found to be superior to placebo, and along with other triptans 
is recommended as first-line therapy for acute treatment of 
moderate to severe migraine. It has the fastest onset of action 
of any triptan, with effects seen as early as ten minutes, and 
has a high rate of improvement in pain and relief of pain at 
one hour. It is also a good option in patients suffering from 
migraine associated with nausea and vomiting.
Comparative trials
There have been few studies of subcutaneous sumatriptan 
using active comparators, but it has been compared with 
intravenous aspirin, oral eletriptan, metoclopramide, prochlo-
rperazine, and trimethobenzamide-diphenhydramine.
In a 1999 study, the ASASUMAMIG Study Group com-
pared intravenous acetylsalicylic acid lysinate (L-ASA, an 
intravenous form of aspirin) and subcutaneous sumatriptan. 
This was a randomized, double-blind, double-dummy, mul-
ticenter, placebo-controlled study including 279 migraine 
patients. Patients were asked to rate their headaches on a 
verbal rating scale, with the primary outcome of the study 
being headache relief. Secondary outcomes included head-
ache relief defined by change in a 100 mm visual analog pain 
scale, number of patients who were pain-free, rate of recur-
rent headaches, changes in migraine-associated symptoms, 
time until the patient could return to work at normal levels, 
and other adverse events.16
The authors found subcutaneous sumatriptan to be 
superior to L-ASA, as measured by the primary outcome 
(91.2% versus 73.9%, P = 0.001). Both medications were 
superior to placebo for migraine relief. Sumatriptan was 
also superior to L-ASA for the secondary outcomes of 
change in visual analog score, proportion of patients who 
were pain-free at 2 hours, and time until the patient could 
return to work. L-ASA performed similarly to subcutaneous 
sumatriptan for some migraine-associated symptoms, such 
as nausea, vomiting, photophobia, phonophobia, and visual 
disturbances. Recurrent headaches 24 hours after treatment 
were similar for both groups (L-ASA 18.2%, sumatriptan 
23.1%, placebo 20%).16
The rate of adverse events was higher for subcutane-
ous sumatriptan than for L-ASA (32.8% versus 7.6%, 
respectively, and 9.3% for placebo). The most common 
adverse events for subcutaneous sumatriptan were tiredness/ 
weariness/fatigue (12.9%), dizziness/vertigo (6.8%), and 
injection site reactions (6.0%). Four participants had chest 
pain. Eleven adverse events were rated as “severe” with-
out further description, with six of these events related to 
sumatriptan.16
In 2005, Schoenen et al compared oral eletriptan 80 mg 
with subcutaneous sumatriptan 6 mg in patients who had 
previously used subcutaneous sumatriptan in a randomized, 
open crossover trial. This was the first study directly com-
paring subcutaneous sumatriptan with an oral triptan and 
used patient preference for future treatment as the primary 
outcome. The authors found no significant difference in 
patient preference between the two drugs (50.6% eletriptan 
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versus 43% subcutaneous sumatriptan, no P value given). 
Secondary outcomes included efficacy of the drugs. One hour 
after administration, subcutaneous sumatriptan was superior 
to eletriptan for both headache relief and number of patients 
who were pain-free. Two hours after administration, subcuta-
neous sumatriptan had a higher rate for headache relief (87% 
subcutaneous sumatriptan versus 82% eletriptan, P , 0.05) 
but the two drugs had similar percentages of patients who 
were pain-free (61% sumatriptan versus 58% eletriptan, no 
P value given).17
In a 2005 study, Friedman et al compared the efficacy 
of intravenous metoclopramide with that of subcutaneous 
sumatriptan in emergency department patients with a chief 
complaint of headache who met International Headache 
Society guidelines for migraine with or without aura. This 
randomized, double-blind, clinical trial had a primary out-
come of change in pain intensity 2 hours after treatment as 
measured by an 11-point pain scale. Of note, the dosing of 
metoclopramide was four 20 mg doses every 30 minutes as 
needed, and it was also given with diphenhydramine for the 
first and third doses. The authors found that both intravenous 
metoclopramide and subcutaneous sumatriptan relieved pain 
to a similar extent at 2 hours. In terms of secondary endpoints, 
more participants treated with intravenous metoclopramide 
were pain-free at 2 hours and participants from both groups 
had similar rates of headache improvement at 24 hours. The 
most common adverse reactions at 2 and 24 hours for both 
groups were weakness, dizziness, and drowsiness, with rates 
being comparable between the two medication groups. At 
one hour, the subcutaneous sumatriptan group did have a 
significantly higher rate of chest heaviness. There were no 
reports of chest pain.18
In 2006, Friedman et al compared subcutaneous sumatrip-
tan with intramuscular trimethobenzamide-diphenhydramine, 
on the basis that intramuscular trimethobenzamide-
  diphenhydramine would be superior to subcutaneous suma-
triptan for relief of acute migraine.
The study was a randomized, double-blind, double-
dummy design completed in the emergency department. 
The primary outcome was decreased pain as measured by 
an 11-point numerical rating scale at 2 hours, with second-
ary outcomes of a four-point pain scale and disability scale. 
Patients were also contacted at 24 hours by telephone for 
follow-up. The study was stopped after a preplanned interim 
analysis by the data monitoring committee because subcu-
taneous sumatriptan showed substantial benefit compared 
with intramuscular trimethobenzamide-diphenhydramine 
after enrollment of 40 patients. At 24-hour follow-up, the 
two groups had   comparable pain relief. After discharge, 
significantly more patients in the subcutaneous sumatriptan 
group had nausea and some limitation to their usual daily 
activities. Both groups had similar rates of side effects 
and need for rescue   medication. The authors concluded 
that subcutaneous sumatriptan was likely superior to 
trimethobenzamide-diphenhydramine, but that trimethoben-
zamide-diphenhydramine was effective and well tolerated, 
with a possible role in patients with contraindications to 
sumatriptan.19
Kostic et al compared subcutaneous sumatriptan with 
intravenous prochlorperazine in a 2010 randomized, double-
blind emergency department study. Sixty-eight patients 
who had a history of migraine and presented with a typical 
migraine headache were included. The primary outcome of 
the study was mean change in pain intensity 80 minutes after 
treatment, or at discharge if the patient was discharged prior 
to 80 minutes after medication administration. Secondary 
outcomes included changes in sedation and nausea reported 
by the patient.20
The authors found that both treatments were effective 
in reduction of headache, with the mean decrease in pain 
intensity being significantly higher for prochlorperazine 
than for sumatriptan. Changes in sedation and nausea were 
not significantly different between the groups. Twenty-eight 
percent of patients in the prochlorperazine group reported 
restlessness but did not require further treatment. No patient 
in the sumatriptan group reported chest pain. Proportions 
of recurrent headache were similar between the medication 
groups at 72 hours (43% intravenous prochlorperazine versus 
63% subcutaneous sumatriptan, 95% CI -31–60).20
In summary, there are few studies in which subcutaneous 
sumatriptan has been compared directly with other drugs. In 
those studies, the efficacy of subcutaneous sumatriptan was 
comparable with oral eletriptan and intravenous metoclopr-
amide, was superior to intravenous aspirin and intramuscular 
trimethobenzamide-diphenhydramine, and was inferior only 
to intravenous prochlorperazine for pain relief.
Primary headaches
Primary headaches are headaches that are not secondary to 
some identified discrete pathology, such as meningitis or 
subarachnoid hemorrhage. These include migraine, probable 
migraine, tension, and cluster headaches.2 Very little is known 
about the differences in etiology and treatment of primary 
headaches. Primary headaches have been reported to account 
for a complaint of headache in the overwhelming majority of 
ambulatory patients.21 In the emergency   department or clinic 
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setting, it has been shown that clinicians can treat primary 
headaches with similar classes of med  ication, regardless of 
headache classification.22–24
Subcutaneous sumatriptan has been shown to work in 
primary headaches.4,5 In a 2007 study, Miner et al used 
subcutaneous sumatriptan as a first-line agent for benign, 
undifferentiated headaches in all patients presenting to the 
emergency department, regardless of migraine history. Type 
of headache at the time of presentation was classified as 
migraine, probable migraine, or tension headache based on 
International Headache Society criteria. All patients received 
subcutaneous sumatriptan 6 mg once enrolled. The primary 
outcome of this study was pain relief among the various 
headache subtypes. A 100 mm visual analog scale was used 
30 and 60 minutes after administration to determine pain 
relief, and patients were contacted 48 hours after treatment to 
assess for adverse events and recurrence of headache. Of the 
167 patients enrolled in this study, 84 (57.1%) had migraine 
headache, 45 (30.7%) had probable migraine headache, and 
18 (12.2%) had tension headache. There was no difference 
in pain relief between the headache subtypes as measured by 
visual analog score, with 50/84 (60%) of migraine patients, 
25/45 (56%) of probable migraine, and 12/18 (67%) expe-
riencing at least a 50% reduction in visual analog score 
(P = 0.72) 60 minutes after treatment.24
Those without a history of migraine headaches had a 
similar rate of good response to subcutaneous sumatriptan as 
compared with those with a history of migraine he  adaches. 
Thirty-six adverse events were recorded, including 
13 patients with chest and neck burning or tightness. All of 
these patients had symptoms for less than 60 minutes and 
electrocardiograms were performed, with no abnormalities 
noted after these symptoms.24
Ninety-five (64.6%) of patients were reached by tele-
phone at 48 hours after enrollment. Sixty-three (66.3%) 
had continued headache, with 26 rating their headache as 
“severe,” six as “moderate,” and 31 as “light”. There was no 
difference between International Headache Society groups 
regarding continued symptoms. The authors concluded 
that subcutaneous sumatriptan is effective for the treat-
ment of primary headaches in the emergency department, 
based on International Headache Society classification of 
headache, with similar rates of adverse events as reported 
previously.24
These findings are similar to those of a 2000 study by 
Lipton et al, where the authors randomized patients to placebo 
or oral sumatriptan in a 4:1 fashion in the clinic setting. All 
patients had a history of migraine, but were instructed to 
take the assigned medication for any headache, regardless of 
whether it was migraine or not. They used diaries to record 
pretreatment characteristics of their headaches, which were 
later classified by the study investigators using International 
Headache Society criteria. Two hundred and forty-nine 
patients were treated for 1576 headaches, 1110 migraine, 
103 migrainous, and 363 tension-type headaches. Sumatriptan 
50 mg orally was superior to placebo in all three headache 
groups 4 hours after dosing.22
All of the patients had a history of migraine in the   Lipton 
et al study, while patients in the Miner et al study did not 
require a previous diagnosis of migraine for inclusion. The 
majority of the patients in these studies had migraine or 
migrainous headache. There was a significant minority in 
both studies with tension-type headaches who had relief 
with sumatriptan. There were no patients in these studies 
with cluster headache. However, it is known that sumatriptan 
is effective in patients with cluster headache.1 Both these 
studies suggest that sumatriptan in any form is an option for 
the treatment of primary headache, provided it is used in the 
appropriate patient population.
Safety
Subcutaneous sumatriptan is safe when it is given to patients 
without known cerebrovascular disease, with rare occurrences 
of serious drug events.25–27 Sumatriptan has been extensively 
studied since it was introduced. In clinical trials through to 
December 1998, more than 88,000 migraine patients had 
treated over 300,000 migraines with sumatriptan, and 2000 
normal healthy volunteers had also been given sumatriptan. 
In a report of marketing data in 1998, there were more than 
nine million patient exposures and over 236 million attacks 
treated with sumatriptan.25 Hall et al conducted a large study 
of 63,575 migraine patients and 77,239 controls with the 
objective of estimating incidence of stroke, cardiovascular 
events, or death in migraine patients and evaluating for an 
association between these events and those treated with 
triptans. Cardiovascular events were defined as myocardial 
infarction, transient ischemic attack, and ischemic heart 
disease. In this study, 13,664 patients were prescribed trip-
tans, and the authors found the risk of these events to be no 
different to that at baseline in the population studied.
Of the different triptan types and formulations, subcu-
taneous sumatriptan appears to have the highest rate of side 
effects, most of which are mild to moderate and transient. 
Common side effects include injection site reactions and the 
so-called “triptan sensations”. These include tingling, numb-
ness, a sensation of warmth, and heaviness and   pressure, 
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principally in the chest and neck. Neurologic symptoms 
include somnolence and dizziness, although there is some 
debate over whether these are a consequence of the migraine 
process or an adverse event of the drug.25,28–30
Rates of adverse events in short-term clinical studies are 
variable, ranging from ,10% to .50%.25,29,30 Injection site 
reactions are the most common side effect, reported in 59% 
of patients who received subcutaneous sumatriptan versus 
24% of those who received placebo in a summary of those 
participating in the short-term clinical trials. More than 80% 
of these adverse events were mild to moderate, with most 
lasting less than 3 hours. Tingling, dizziness, and warm/
hot sensations were reported by ,15% in the subcutaneous 
sumatriptan groups versus ,4% in the placebo groups. The 
remainder of adverse events reported, including burning 
sensation, feeling of heaviness or tightness, flushing, neck 
pain/stiffness, weakness, and numbness, accounted for less 
than 10% in the subcutaneous sumatriptan group and less 
than 4% in the placebo group. In long-term clinical trials 
lasting up to two years, the types of adverse events were 
similar to those in the short-term clinical trials.25 The fre-
quency of adverse events was similar to or less than that in 
the short-term clinical trials.25,28 In total, 6%–12% of patients 
using subcutaneous sumatriptan withdrew from long-term 
clinical trials because of adverse events versus 7% and 4% 
of those using tablet and nasal spray forms of sumatriptan, 
respectively.25,28,30,31
The proportion of patients reporting chest symptoms, 
such as tightness and pressure, is higher in clinical practice 
than in the clinical trials, in the range of 20%–40% in clini-
cal practice and 3%–5% in the clinical trials. The majority 
of patients experiencing these symptoms are young and 
middle-aged women, who in general have a lower body mass 
index and lower cardiovascular risk. Approximately 50% 
of patients in the clinical trials also experienced feelings of 
tightness and heaviness in other areas of the body. However, 
the incidence of myocardial ischemia with these events has 
been rare. The overwhelming majority of these events have 
showed no causal relationship to myocardial ischemia by 
electrocardiogram, angiography, cardiac enzyme measure-
ment, or temporal data.26,29,33,34
The incidence of serious cardiac and cerebrovascular 
events with subcutaneous sumatriptan is relatively rare. 
Sumatriptan is contraindicated in patients with coronary 
artery disease (CAD), cerebrovascular disease, arterial 
disease (eg, Raynaud’s), or peripheral arterial disease due 
to reported events of myocardial infarction, life-threatening 
cardiac dysrhythmias, and death. It is recommended that 
sumatriptan is not given to patients in whom CAD status is 
unclear or to those with risk factors, such as hypertension, 
hypercholesterolemia, smoking, diabetes mellitus, or a 
strong family history of CAD. This is excluding patients who 
have these risk factors but have had no evidence of CAD, 
cerebrovascular disease, or peripheral arterial disease after 
cardiovascular evaluation.25,28,34
Postmarketing data represent a valuable source of infor-
mation on adverse events. They provide large numbers of 
patient exposures to a drug in clinical practice, increasing the 
detection of rare events, and also provide ongoing informa-
tion about the how the drug is tolerated in the population. 
However, the utility of the information is limited compared 
with data from a clinical trial. There are no control groups 
or follow-up of outcomes, there is a general lack of uniform 
definition of adverse events, and event reporting is left to the 
discretion of patients and/or caregivers. It is impossible to 
calculate the true incidence of adverse events for sumatriptan 
because we do not know the total number of adverse events 
or the total number of patients who use sumatriptan.25,28
In a review of postmarketing data between 1992 and 
December 1998, there were 451 reports of serious cardiac 
adverse events within 24 hours of taking sumatriptan. These 
events include myocardial ischemia, angina/chest pain, 
increased cardiac enzymes, any ST segment change, seri-
ous dysrhythmias, cardiovascular test abnormalities, asys-
tole, ventricular tachycardia or fibrillation, and vasospasm. 
Most patients with adverse cardiac events had risk factors 
for CAD or were known to have CAD. In the same review, 
92   cardiovascular and 10 neurologic deaths were reported 
at any post-dose time of subcutaneous sumatriptan, tab-
let, or nasal spray in nine million patients for more than 
236 migraine attacks.25 This indicates that in the clinical 
setting there is likely to be a cardiovascular risk from suma-
triptan, and that it is small but likely higher in patients with 
known cardiovascular disease.
Vasoconstriction is mostly mediated by 5-HT1B and 
5-HT2A receptors in human coronary arteries.35 Triptans 
are most selective for 5-HT1B and 5-HT1D receptors. In the 
isolated or in vitro human coronary artery, 5-HT2A recep-
tors generally produce greater contraction than 5-HT1B 
receptors.36–41
In a study of the cardiovascular effects of triptans, several 
triptans, including sumatriptan, showed small comparable 
contractions in isolated human coronary arteries from organ 
donor patients who were deceased from noncardiac e  tiologies. 
The authors found that the ratio between unbound maximum 
plasma concentrations (Cmax) of triptans after   administration 
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of a clinically effective dose and the concentration of dif-
ferent compounds required to obtain 50% contraction of 
the coronary artery (EC50) was low. This ratio provides a 
relationship between maximal plasma concentrations of a 
triptan and its vasoconstrictor effect. A Cmax/EC50 ratio of 
1 would produce 50% maximum contraction, and all triptans 
were below 0.4. This study would suggest that triptans are 
not expected to cause significant CAD and do not produce 
significant coronary artery contraction at the doses typically 
used to treat migraine headaches.40,42
In a more recent study, Edvinsson et al examined the 
Cmax/EC50 ratio of several triptans, in addition to quantifying 
their vasoconstrictor effect in isolated human cerebral and 
coronary arteries and the number of 5-HT1B receptors in ath-
erosclerotic and normal coronary arteries. This study found 
the triptans were three times more potent as vasoconstrictors 
in cerebral arteries than in coronary arteries. No difference 
was found in the expression of 5-HT1B receptors in athero-
sclerotic and normal coronary arteries. The Cmax/EC50 ratio 
for cerebral arteries approached 1, while the Cmax/EC50 ratio 
for coronary arteries was much lower, the highest being sub-
cutaneous sumatriptan with a mean ratio of 0.11 (0.08–0.57). 
These findings support the clinical observation that triptans 
are safe drugs with a minimal risk of adverse coronary events 
in the appropriate patient population.43
Building on the results of the above studies, multiple 
studies have shown a clinically insignificant decrease in mean 
coronary artery diameter when subcutaneous sumatriptan is 
given at therapeutic levels or supratherapeutic levels to indi-
viduals without migraine and without CAD.44–48 Additionally, 
the relevant study results are also consistent with those of 
a double-blind, crossover, positron emission tomography 
study in which images of the heart were interpreted before 
and 10 minutes after administration of subcutaneous suma-
triptan or placebo in 19 patients. All patients were women, 
had a low risk of cardiovascular disease, and were younger 
than 62 years. Three women developed neck tightness and 
one developed chest tightness after receiving subcutaneous 
sumatriptan. Overall, no significant change in myocardial 
perfusion was observed, including in the patients with neck 
or chest tightness.49
It is not known whether sumatriptan has an effect on 
diseased coronary arteries. In one small study by Glaxo 
Wellcome in 1994, 16 patients with at least 50% stenosis 
in at least one vessel segment were given subcutaneous 
sumatriptan (n = 11) or placebo (n = 5). There were no sig-
nificant changes in mean coronary artery diameter between 
the treatment groups.25 The main limitation of this study was 
the small sample size. Given the contraindication of suma-
triptan in patients with known CAD, this study is unlikely to 
be repeated. In a post hoc study of isolated human coronary 
arteries, the same authors examined the relationship between 
endothelial integrity in a coronary artery segment and the 
degree of contraction after administration of sumatriptan. 
They found that the degree of coronary vasoconstriction 
was inversely proportional to the integrity of the coro-
nary endothelium, suggesting that sumatriptan has a more 
potent vasoconstrictive effect in healthy coronary arteries.50 
Although the vasoconstrictor effect in the coronary arteries 
is widely accepted as clinically insignificant in patients with 
no CAD, it is possible that even a small constricting effect 
in those with pre-existing CAD could cause myocardial 
ischemia.
The Triptan Cardiovascular Safety Expert Panel published 
a consensus statement in 2004 regarding the cardiovascular 
safety profile of triptans in the acute treatment of migraine. 
The authors concluded that the chest symptoms associated 
with triptan sensations in placebo-controlled clinical trials, 
excluding those with significant cardiovascular risk factors, 
were generally “transient, mild, and nonserious”. They also 
concluded that in long-term clinical trials which excluded 
participants with known ischemic heart disease, the chest 
symptoms reported after triptan use were not associated 
with serious cardiovascular outcomes. Their conclusion was 
that triptans have minimal effects on the coronary arteries at 
therapeutic plasma concentrations.34
Postmarketing surveillance data in the consensus state-
ment were also addressed, with the caveat that one cannot 
depend on surveillance data alone to examine for a causal 
association between triptan use and serious cardiovascular 
adverse events. The authors stated that the rate of serious car-
diovascular adverse events is very small given the widespread 
use of triptans. However, it was emphasized that while this 
risk is low, it cannot be ignored, because use of triptans can 
lead to serious adverse effects, including death.34
In conclusion, subcutaneous sumatriptan has the highest 
rate of side effects of the triptans, with most side effects last-
ing less than 3 hours and characterized as mild to moderate. 
Of the triptans available, subcutaneous sumatriptan has the 
fastest onset of action, but has also been associated with the 
most adverse events. However, in general, it is well toler-
ated by patients. There is a rare but well described risk of 
serious cardiovascular events associated with subcutaneous 
sumatriptan, as with all triptans in general. It is contraindi-
cated in patients with known cerebrovascular disease, and 
clinicians must be vigilant in assessing for cerebrovascular 
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risk factors in patients with unknown disease status prior 
to drug ad  ministration. It is important to consider the risk-
benefit profile for every individual prior to giving subcutane-
ous sumatriptan, but for most patients sumatriptan is a safe 
approach for the treatment of migraine headache.
Patient acceptance and compliance
Subcutaneous sumatriptan has been shown to be effective 
for acute primary headache, with a rapid onset of action, and 
is a good option for those with nausea and vomiting. Side 
effects with this medication are generally mild to moderate 
and typically do not last long. However, of the triptan com-
pounds and formulations, subcutaneous sumatriptan has the 
highest reported rate of side effects. Serious adverse events 
are rare in those for whom the drug is indicated. However, 
many patients dislike subcutaneous administration and 
“triptan sensations”. Although patients value efficacy and 
onset of action in migraine treatment, other aspects of treat-
ment are also important. Many newer migraine studies also 
examine patient satisfaction and preference as an endpoint, 
recognizing the value of a well rounded approach to migraine 
treatment.
In 1998, Dahlof and Saiers compared subcutaneous 
sumatriptan and oral sumatriptan use in a population of 707 
  Swedish patients with migraine, who in total had adminis-
tration of over 76,000 subcutaneous sumatriptan injections, 
56,000 100 mg tablets, and 20,000 50 mg tablets. The authors 
undertook a telephone survey of patients previously diag-
nosed at the clinic with migraine who had used subcutane-
ous or oral sumatriptan. Overall, oral sumatriptan was more 
frequently used than subcutaneous sumatriptan. Fifty-one 
percent of patients used sumatriptan 100 mg most frequently, 
22% used sumatriptan 50 mg tablets most frequently, and 
21% used sumatriptan injection most frequently. Oral 
sumatriptan was preferred to subcutaneous sumatriptan by 
the patients surveyed. Thirty-two percent of patients overall 
preferred oral sumatriptan 100 mg, 15% preferred subcutane-
ous sumatriptan, and 46% did not state a preference. The most 
common reason for tablet preference was fewer side effects 
and ease of administration. Subcutaneous sumatriptan was 
rated by patients as the most effective dosing for  mulation. 
Thirty-eight percent said it was the most effective form as 
compared with 14% and 4% rating sumatriptan 100 mg 
and 50 mg tablets as most effective, respectively, with 45% 
not stating a preference. Of those who rated subcutaneous 
sumatriptan as most effective, efficacy and quick onset of 
action were the most common reasons noted for giving the 
top rating. Ninety-one percent stated efficacy was the main 
reason for preferring the injection. Of those who found the 
tablets to be most effective, the reasons given were fewer 
side effects and lack of experience with other dosing forms. 
Side effects were less frequent in those who used sumatriptan 
tablets.51
Overall, 94% of 602 patients who used sumatriptan 
during the study rated sumatriptan as better or much better 
than previous therapies used for migraine. Listed previous 
therapies did not include other triptans. Just under 15% of the 
707 patients had stopped using sumatriptan. The most fre-
quently cited reasons for no longer using sumatriptan were its 
short duration of effect, concern about side effects, and lack 
of efficacy in controlling migraine pain. A large percentage 
of patients did not have an overall drug preference.51
This study illustrates how different dosing forms of 
sumatriptan can be used by migraine patients. As the authors 
state in their discussion, the results suggest that subcutaneous 
sumatriptan can be used in patients whose primary concern 
with treatment is speed of onset and efficacy of pain relief 
rather than possible adverse events. Similarly, oral sumatrip-
tan may be a better agent in patients who have experienced 
some adverse effects from subcutaneous sumatriptan and 
wish to avoid them, or who are more willing to risk inferior 
treatment efficacy in order to avoid adverse events.51
A retrospective study from 2004 examined reasons for 
patients switching triptans at a tertiary headache center. 
  Participants included patients followed for migraine head-
aches for at least one year who were using a triptan for acute 
migraine management and had previously used at least one 
other triptan or different triptan formulation.52
Patients who used subcutaneous sumatriptan initially were 
significantly less likely to switch because of “in  complete or 
no relief” as compared with all other drugs studied, which 
included oral sumatriptan 25, 50, and 100 mg, sumatrip-
tan nasal spray, zolmitriptan, rizatriptan, and naratriptan. 
S  ubcutaneous sumatriptan performed comparably or better 
than other drugs in other categories such as recurrence, time 
to relief, inconsistency, and “other triptan or formulation 
is better”. Nearly 20% of patients who had initially used 
subcutaneous sumatriptan and switched to another triptan or 
formulation did return to using subcutaneous sumatriptan. 
Those who used subcutaneous sumatriptan first were more 
likely to switch because of side effects (39% of patients) 
than those who first used sumatriptan 25 mg and 50 mg, 
zolmitriptan, rizatriptan, and naratriptan.
This study highlights the variety of reasons patients 
switch triptans or drug formulations. Similar to previous 
findings, subcutaneous sumatriptan performed well compared 
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with other triptans in area such as efficacy, time to relief, 
and headache recurrence, but had the highest percentage of 
patients switching due to adverse events.52
Similar findings were reported in a 2010 study in which 
343 migraine patients answered a questionnaire regarding 
their patterns of triptan use and adverse events. The most 
frequently used triptan was sumatriptan and the most frequent 
triptan discontinued was subcutaneous sumatriptan. The 
majority of patients (72%) continued to use triptans, while 
28% discontinued use of triptans altogether. Of patients 
continuing to take triptans, 85% of those continued their 
use of the medication because of its efficacy. Most patients 
discontinued the use of triptans because of adverse events 
(59%) and not because of drug ineffectiveness.32
A pilot study that looked at patient preference for smaller 
doses of subcutaneous sumatriptan compared 3 mg versus 
6 mg of subcutaneous sumatriptan for the treatment of acute 
migraine headache. Thirty patients were enrolled in this open 
crossover study. Eighty percent of patients preferred the 
3 mg dose to the 6 mg dose when asked, “After trying both 
doses, which dose do you prefer?” Although no statistical 
tests were applied, the proportions of pain-free responses 
were similar in both groups, with 57% of the 3 mg patients 
reporting being pain-free at one hour versus 53% being pain-
free in the 6 mg group. At 2 hours, 87% were pain-free in 
the 3 mg group and 80% were pain-free in the 6 mg group. 
More side effects were reported with the 6 mg dose than 
with the 3 mg dose.53
Recently introduced is a needle-free form of sumatrip-
tan, whereby subcutaneous sumatriptan is injected through 
a small hole in the skin created by a ram and piston system 
under compressed nitrogen gas. This system has been shown 
to be bioequivalent to subcutaneous sumatriptan delivered 
with a needle-based system and can be used successfully by 
migraine patients.54,55 This may offer an additional route of 
administration for patients intolerant of subcutaneous dosing 
using a needle.
Conclusion
Sumatriptan, in both its oral and subcutaneous form, is an 
effective treatment for acute migraine headache, and can 
be used in patients with known migraine syndrome and in 
those with primary headaches when a secondary cause has 
been excluded. Subcutaneous sumatriptan and other triptans 
are recommended as a first-line treatment for moderate to 
severe acute migraine based on the existing literature and 
expert consensus. Subcutaneous sumatriptan may be most 
effectively used in patients with moderate to severe migraine 
headache associated with nausea and vomiting. It has also 
performed well versus other medications for treatment of 
migraine in limited comparative trials.
Sumatriptan is associated with a rare but well described 
risk of cardiovascular adverse events. For this reason, it 
should not be used in patients with known cerebrovascu-
lar disease. Its use should also be limited in patients with 
cardiovascular risk factors whose cerebrovascular disease 
status is unknown. Injection site reactions and triptan 
sensations are the most common side effects of subcu-
taneous sumatriptan. Further, subcutaneous sumatriptan 
has the highest rate of side effects of all the triptans and 
their formulations, and was reported to be at least 50% in 
one study.
In patient preference and compliance studies, patients 
who prefer subcutaneous sumatriptan do so because of its 
efficacy and speed of onset. The most common reason for 
discontinuation of subcutaneous sumatriptan is adverse drug 
reactions. The subcutaneous formulation appears to be more 
effective than the oral formulation, but the oral route appears 
to be better tolerated. Either formulation appears to be a good 
first-line agent for the treatment of acute migraine headache. 
It is important to consider the needs of the patient, their past 
medical history, and what aspects of migraine treatment are 
most important to the patient when considering treatment of 
acute migraine or primary headache.
Disclosure
The authors state there are no commercial, financial, or other 
relationships in any way related to this work that could create 
a potential conflict of interest.
References
1.  Law S, Derry S, Moore RA. Triptans for acute cluster headache. 
Cochrane Database Syst Rev. 2010;4:008042.
2.  Lipton RB, Bigal ME, Steiner TJ, Silberstein SD, Olesen J. Classification 
of primary headaches. Neurology. 2004;63:427–435.
3.  Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: A com-
parative review of pharmacology, pharmacokinetics, and efficacy. Drugs. 
2000;60:1259–1287.
4.  Shields KG, Goadsby PJ. Serotonin receptors modulate trigeminovascular 
responses in the ventroposteromedial nucleus of thalamus: a migraine 
target? Neurobiol Dis. 2006;23:491–501.
5.  Sprenger T, Goadsby PJ. Migraine pathogenesis and state of pharmaco-
logical treatment options. BMC Med. 2009;7:71.
6.  Hoskin K, Kaube H, Goadsby PJ. Sumatriptan can inhibit trig  eminal 
afferents by an exclusively neural mechanism. Brain. 1996;119: 
1419–1428.
7.  Goadsby PJ. The pharmacology of headache. Prog Neurobiol. 2000;62: 
509–525.
8.  Levy D, Jakubowski M, Burstein R. Disruption of communication 
between peripheral and central trigeminovascular neurons mediates the 
antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad 
Sci U S A. 2004;101:4274–4279.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
35
SC sumatriptan in migraine and primary headachePatient Preference and Adherence 2012:6
  9.  Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) 
receptor in the periaqueductal gray inhibits nociception. Ann Neurol. 
2004;56:371–381.
  10.  Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H. 
Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 
1991;265:2831–2835.
  11.  Treatment of migraine attacks with sumatriptan. The Subcu  taneous 
Sumatriptan International Study Group. N Engl J Med. 1991;325: 
316–321.
  12.  Gawel MJ, Worthington I, Maggisano A. A systematic review of the 
use of triptans in acute migraine. Can J Neurol Sci. 2001;28:30–41.
  13.  Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological 
treatments for acute migraine: quantitative systematic review. Pain. 
2002;97:247–257.
  14.  Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment 
of migraine – revised report of an EFNS task force. Eur J Neurol. 
2009;16:968–981.
  15.  Silberstein SD. Practice parameter: Evidence-based guidelines for 
migraine headache (an evidence-based review). Report of the Quality 
Standards Subcommittee of the American Academy of Neurology. 
Neurology. 2000;55:754–763.
  16.  Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysi-
nate compared with subcutaneous sumatriptan and parenteral placebo 
in the acute treatment of migraine. A double-blind, double-dummy, 
randomized, multicenter, parallel group study. Cephalalgia. 1999;19: 
581–588.
  17.  Schoenen J, Pascual J, Rasmussen S, Sun W, Sikes C, Hettiarachchi J. 
Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 
6 mg: results of a crossover study in patients who have recently used 
subcutaneous sumatriptan. Eur J Neurol. 2005;12:108–117.
  18.  Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide ver-
sus sumatriptan for the emergency department treatment of migraines. 
Neurology. 2005;64:463–468.
  19.  Friedman BW, Hochberg M, Esses D, et al. A clinical trial of 
trimethobenzamide/diphenhydramine versus sumatriptan for acute 
migraines. Headache. 2006;46:934–941.
  20.  Kostic MA, Gutierrez FJ, Rieg TS, Moore TS, Gendron RT. A pro-
spective randomized trial of intravenous prochlorperazine versus 
subcutaneous sumatriptan in acute migraine therapy in the emergency 
department. Ann Emerg Med. 2010;56:1–6.
  21.  Morgenstern LB, Huber JC, Luna-Gonzales H, et al. Headache in the 
emergency department. Headache. 2001;41:537–541.
  22.  Lipton RB, Stewart WF, Cady R, et al. Sumatriptan for the range 
of headaches in migraine sufferers: results of the Spectrum study. 
  Headache. 2000;40:783–791.
  23.  Trainor A, Miner J. Pain treatment and relief among patients with primary 
headache subtypes in the ED. Am J Emerg Med. 2008;26:1029–1034.
  24.  Miner JR, Smith SW, Moore J, Biros M. Sumatriptan for the treatment 
of undifferentiated primary headaches in the emergency department. 
Am J Emerg Med. 2007;25:60–64.
  25.  Welch KM, Mathew NT, Stone P, Rosamond W, Saiers J, Gutt  erman D. 
Tolerability of sumatriptan: clinical trials and post-marketing expe  rience. 
Cephalalgia. 2000;20:687–695.
  26.  Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the 
risks of stroke, cardiovascular disease, and death in practice. Neurology. 
2004;62:563–568.
  27.  O’Quinn S, Davis RL, Gutterman DL, Pait GD, Fox AW. Prospective 
large-scale study of the tolerability of subcutaneous sumatriptan for 
acute treatment of migraine. Cephalalgia. 1999;19:223–231.
  28.  Nappi G, Sandrini G, Sances G. Tolerability of the triptans: clinical 
implications. Drug Saf. 2003;26:93–107.
  29.  Brown EG, Endersby CA, Smith RN, Talbot JC. The safety and toler-
ability of sumatriptan: an overview. Eur Neurol. 1991;18:33–37.
  30.  Gross ML, Kay J, Turner AM, Jewsbury J, Cleal AL. Long-term efficacy 
of subcutaneous sumatriptan using a novel self-injector. Headache. 
1995;35:601–606.
  31.  Tansey MJ, Pilgrim AJ, Martin PM. Long-term experience with suma-
triptan in the treatment of migraine. Eur Neurol. 1993;33:310–315.
  32.  Ferrari A, Spaccapelo L, Sternieri E. Pharmacoepidemiology of triptans 
in a headache centre. Cephalalgia. 2010;30:847–854.
  33.  Visser WH, Jaspers MN, de Vriend RH, Ferrari MD. Chest symptoms 
after sumatriptan: a two-year clinical practice review in 735 consecutive 
migraine patients. Cephalalgia. 1996;16:554–559.
  34.  Dodick D, Lipton RB, Martin V , Papademetriou V , et al. Consensus 
statement: cardiovascular safety profile of triptans (5HT agonists) in 
the acute treatment of migraine. Headache. 2004;44:414–425.
  35.  Nilsson T, Longmore J, Shaw D, et al. Characterisation of 5-HT recep-
tors in human coronary arteries by molecular and pharmacological 
techniques. Eur J Pharm. 1999;372:49–56.
  36.  Bax WA, Renzenbrink GJ, Van Heuven-Nolsen D, Thijssen EJ, Bos E, 
Saxena PR. 5HT receptors mediating contractions of the isolated human 
coronary artery. Eur J Pharm. 1993;239:203–210.
  37.  Connor HE, Feniuk W, Humphrey PP. 5-Hydroxytryptamine contracts 
human coronary arteries predominantly via 5-HT2 receptor activation. 
Eur J Pharm. 989;161:91–94.
  38.  Chester AH, Martin GR, Bodelsson M, et al. 5-hydroxytryptamine 
receptor profile in healthy and diseased human epicardial coronary 
arteries. Cardiovasc Res. 1990;24:932–937.
  39.  Cocks TM, Kemp BK, Pruneau D, Angus JA. Comparison of contractile 
responses to 5-hydroxytryptamine and sumatriptan in human isolated 
coronary artery: synergy with the thromboxane A2-receptor agonist, 
U46619. Br J Pharmacol. 1993;110:360–368.
  40.  Maassen VanDenBrink A, Reekers M, Bax WA, Ferrari MD, 
Saxena PR. Coronary side-effect potential of current and prospective 
antimigraine drugs. Circulation. 1998;98:25–30.
  41.  Toda N, Okamura T. Comparison of the response to 5-carboxamido-
tryptamine and serotonin in isolated human, monkey, and dog coronary 
arteries. J Pharmacol Exp Ther. 1990;253:676–682.
  42.  van den Broek RW, Maassen VanDenBrink A, de Vries R, et al. Pharma-
cological analysis of contractile effects of eletriptan and sumatriptan on 
human isolated blood vessels. Eur J Pharmacol. 2000;407:165–173.
  43.  Edvinsson L, Uddman E, Wackenfors A, Davenport A, Longmore J, 
Malmsjo M. Triptan-induced contractile (5-HT1B receptor) responses 
in human cerebral and coronary arteries: relationship to clinical effect. 
Clin Sci. 2005;109:335–342.
  44.  MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. Effect 
of subcutaneous sumatriptan, a selective 5HT1 receptor agonist, on the 
systemic, pulmonary, and coronary circulation. Circulation. 1993;87: 
401–405.
  45.  Macintyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. The 
effect of i.v. sumatriptan, a selective 5HT1 receptor agonist, on central 
haemodynamics and the coronary circulation. Br J Clin Pharmacol. 
1992;34:541–546.
  46.  Hood S, Birnie D, Swan L, et al. Effects of subcutaneous naratriptan on 
systemic and pulmonary haemodynamics and coronary artery diameter 
in humans. J Cardiovasc Pharmacol. 1999;34:89–94.
  47.  Muir DF, McCann GP, Swan L, Clark AL, Hillis WS. Hemodynamic 
and coronary effects of intravenous eletriptan, a 5-HT1B/1D receptor 
agonist. Clin Pharmacol Ther. 1999;66:85–90.
  48.  Goldstein JA, Massey KD, Kirby S, et al. Effect of high-dose intra-
venous eletriptan on coronary artery diameter. Cephalalgia. 2004;24: 
515–521.
  49.  Lewis PJ, Barrington SF, Marsden PK, Maisey MN, Lewis LD. A study 
of the effects of sumatriptan on myocardial perfusion in healthy female 
migraineurs using 13NH3 positron emission tomography. Neurology. 
1997;48:1542–1550.
  50.  Maassen VanDenBrink A, Bax WA, Ramrattan NN, Ferrari MD, 
Saxena PR. Human isolated coronary artery contraction to sumatriptan: 
a post hoc analysis. Cephalalgia. 1999;19:651–654.
  51.  Dahlöf CG, Saiers J. Sumatriptan injection and tablets in clinical 
practice: Results of a survey of 707 migraineurs. Headache. 1998;38: 
756–763.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
36
Moore and MinerPatient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal focusing on the growing importance of patient 
preference and adherence throughout the therapeutic continuum. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and 
their role in developing new therapeutic modalities and compounds to 
optimize clinical outcomes for existing disease states are major areas of 
interest. This journal has been accepted for indexing on PubMed Central. 
The manuscript management system is completely online and includes a 
very quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Patient Preference and Adherence 2012:6
  52.  Sheftell FD, Feleppa M, Tepper SJ, Volcy M, Rapoport AM, Bigal ME. 
Patterns of use of triptans and reasons for switching them in a tertiary 
care migraine population. Headache. 2004;44:661–668.
  53.  Landy SH, McGinnis JE, McDonald SA. Pilot study evaluating pref-
erence for 3 mg versus 6 mg subcutaneous sumatriptan. Headache. 
2005;45:346–349.
  54.  Brandes JL, Cady RK, Freitag FG, et al. Needle-free subcutaneous 
sumatriptan: bioequivalence and ease of use. Headache. 2009;49: 
1435–1444.
  55.  Cady RK, Aurora SK, Brandes JL, et al. Satisfaction with and confidence 
in needle-free subcutaneous sumatriptan in patients currently treated 
with triptans. Headache. 2011;51:1202–1211.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
37
SC sumatriptan in migraine and primary headache